source
- Celea Therapeutics raises $180 million to advance next-generation IPF drug deupirfenidoneCelea Therapeutics, a PureTech Health spinout, announced a $180 million venture round to fund development of its next-generation idiopathic pulmonary fibrosis (IPF) therapy, deupirfenidone. The ro…
- FDA Grants First Gene-Therapy Approval for Children 2+ with Sickle Cell DiseaseThe U.S. Food and Drug Administration issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged two years and older who have sickle cell disease with recurrent vaso-oc…